Targeting of plasminogen activator inhibitor 1 improves fibrinolytic therapy for tetracycline-induced pleural injury in rabbits

American Journal of Respiratory Cell and Molecular Biology

Volumn 52, Issue 4, 2015, Pages 429-437

  Florova, Galina ^a   Azghani, Ali ^b   Karandashova, Sophia ^a   Schaefer, Chris ^a   Koenig, Kathleen ^a   Stewart Evans, Kris ^a   Declerck, Paul J ^c   Idell, Steven ^a   Komissarov, Andrey A ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

^b UNIVERSITY OF TEXAS AT TYLER   (United States)

^c DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

Author keywords

Animal model; Fibrinolytic therapy; Monoclonal antibodies; Plasminogen activator inhibitor 1; Prourokinase

Indexed keywords

ALPHA 2 MACROGLOBULIN; ANTIGEN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 33H1F7; MONOCLONAL ANTIBODY 8H9D4; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE; PROUROKINASE; TETRACYCLINE; UNCLASSIFIED DRUG; UROKINASE; FIBRINOLYTIC AGENT; SERINE PROTEINASE INHIBITOR;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INACTIVATION; EX VIVO STUDY; FEMALE; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PLEURA DISEASE; PLEURA FLUID; PLEURA INJURY; TREATMENT OUTCOME; ANIMAL; CHEMICALLY INDUCED; DOSE RESPONSE; IMMUNOLOGY; PLEURAL DISEASES; PRECLINICAL STUDY; RABBIT;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; FIBRINOLYTIC AGENTS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLEURAL DISEASES; RABBITS; SERINE PROTEINASE INHIBITORS; TETRACYCLINE;

EID: 84929658280     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2014-0168OC     Document Type: Article

References (35)

1. Maskell NA, Davies CW, Nunn AJ, Hedley EL, Gleeson FV, Miller R, Gabe R, Rees GL, Peto TE, Woodhead MA, et al. UK controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med 2005;352: 865-874.
2. Rahman NM, Maskell NA, West A, Teoh R, Arnold A, Mackinlay C, Peckham D, Davies CW, Ali N, Kinnear W, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med 2011;365:518-526.
3. Sonnappa S, Cohen G, Owens CM, van Doorn C, Cairns J, Stanojevic S, Elliott MJ, Jaffe A. Comparison of urokinase and video-assisted thoracoscopic surgery for treatment of childhood empyema. Am J Respir Crit Care Med 2006;174:221-227.
4. Davies HE, Lee YC. Management of malignant pleural effusions: questions that need answers. Curr Opin Pulm Med 2013;19: 374-379.
5. Abu-Daff S, Maziak DE, Alshehab D, Threader J, Ivanovic J, Deslaurier V, Villeneuve PJ, Gilbert S, Sundaresan S, Shamji F, et al. Intrapleural fibrinolytic therapy (IPFT) in loculated pleural effusions-analysis of predictors for failure of therapy and bleeding: a cohort study. BMJ Open 2013;3:e001887.
6. Colice L, Idell S. Counterpoint: should fibrinolytics be routinely administered intrapleurally for management of a complicated parapneumonic effusion? No. Chest 2014;145:17-20.
7. Cameron R, Davies HR. Intra-pleural fibrinolytic therapy versus conservative management in the treatment of adult parapneumonic effusions and empyema. Cochrane Database Syst Rev 2008;(2):CD002312.
8. van Mourik JA, Lawrence DA, Loskutoff DJ. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem 1984;259:14914-14921.
9. Carrell RW, Evans DL, Stein PE. Mobile reactive centre of serpins and the control of thrombosis. Nature 1991;353:576-578. [Published erratum appears in Nature 364:737.]
10. Hardaway RM, Harke H, Williams CH. Fibrinolytic agents: a new approach to the treatment of adult respiratory distress syndrome. Adv Ther 1994;11:43-51.
11. Hardaway RM, Williams CH, Marvasti M, Farias M, Tseng A, Pinon I, Yanez D, Martinez M, Navar J. Prevention of adult respiratory distress syndrome with plasminogen activator in pigs. Crit Care Med 1990;18:1413-1418.
12. Bouros D, Tzouvelekis A, Antoniou KM, Heffner JE. Intrapleural fibrinolytic therapy for pleural infection. Pulm Pharmacol Ther 2007; 20:616-626.
13. Idell S. Update on the use of fibrinolysins in pleural disease. Clin Pulm Med 2005;12:184-190.
14. Corcoran JP, Hallifax R, Rahman NM. New therapeutic approaches to pleural infection. Curr Opin Infect Dis 2013;26:196-202.
15. Idell S, Zwieb C, Boggaram J, Holiday D, Johnson AR, Raghu G. Mechanisms of fibrin formation and lysis by human lung fibroblasts: influence of TGF-Beta and TNF-alpha. Am J Physiol 1992;263: L487-L494.
16. Philip-Joet F, Alessi MC, Philip-Joet C, Aillaud M, Barriere JR, Arnaud A, Juhan-Vague I. Fibrinolytic and inflammatory processes in pleural effusions. Eur Respir J 1995;8:1352-1356.
17. Karandashova S, Florova G, Azghani AO, Komissarov AA, Koenig K, Tucker TA, Allen TC, Stewart K, Tvinnereim A, Idell S. Intrapleural adenoviral delivery of human plasminogen activator inhibitor-1 exacerbates tetracycline-induced pleural injury in rabbits. Am J Respir Cell Mol Biol 2013;48:44-52.
18. Komissarov AA, Florova G, Azghani A, Karandashova S, Kurdowska AK, Idell S. Active alpha-macroglobulin is a reservoir for urokinase after fibrinolytic therapy in rabbits with tetracycline-induced pleural injury and in human pleural fluids. Am J Physiol Lung Cell Mol Physiol 2013;305:L682-L692.
19. Declerck PJ, Gils A. Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpin. Semin Thromb Hemost 2013;39:356-364.
20. Komissarov AA, Declerck PJ, Shore JD. Mechanisms of conversion of plasminogen activator inhibitor 1 from a suicide inhibitor to a substrate by monoclonal antibodies. J Biol Chem 2002;277: 43858-43865.
21. Komissarov AA, Andreasen PA, Bodker JS, Declerck PJ, Anagli JY, Shore JD. Additivity in effects of vitronectin and monoclonal antibodies against alpha-helix f of plasminogen activator inhibitor-1 on its reactions with target proteinases. J Biol Chem 2005;280:1482-1489.
22. Komissarov AA, Zhou A, Declerck PJ. Modulation of serpin reaction through stabilization of transient intermediate by ligands bound to alpha-helix F. J Biol Chem 2007;282:26306-26315.
23. Komissarov AA, Andreasen PA, Declerck PJ, Kamikubo Y, Zhou A, Gruber A. Redirection of the reaction between activated protein C and a serpin to the substrate pathway. Thromb Res 2008;122:397-404.
24. Idell S, Azghani A, Chen S, Koenig K, Mazar A, Kodandapani L, Bdeir K, Cines D, Kulikovskaya I, Allen T. Intrapleural low-molecular-weight urokinase or tissue plasminogen activator versus single-chain urokinase in tetracycline-induced pleural loculation in rabbits. Exp Lung Res 2007;33:419-440.
25. Idell S, Girard W, Koenig KB, McLarty J, Fair DS. Abnormalities of pathways of fibrin turnover in the human pleural space. Am Rev Respir Dis 1991;144:187-194.
26. Komissarov AA, Mazar AP, Koenig K, Kurdowska AK, Idell S. Regulation of intrapleural fibrinolysis by urokinase-alphamacroglobulin complexes in tetracycline-induced pleural injury in rabbits. Am J Physiol Lung Cell Mol Physiol 2009;297: L568-L577.
27. Midde KK, Batchinsky AI, Cancio LC, Shetty S, Komissarov AA, Florova G, Walker KP III, Koenig K, Chroneos ZC, Allen T, et al. Wood bark smoke induces lung and pleural plasminogen activator inhibitor 1 and stabilizes its mrna in porcine lung cells. Shock 2011;36:128-137.
28. Wu JH, Diamond SL. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions. Thromb Haemost 1995;74:711-717.
29. Komissarov AA, Florova G, Idell S. Effects of extracellular DNA on plasminogen activation and fibrinolysis. J Biol Chem 2011;286: 41949-41962.
30. Debrock S, Declerck PJ. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms. Biochim Biophys Acta 1997;1337:257-266.
31. Bijnens AP, Gils A, Knockaert I, Stassen JM, Declerck PJ. Importance of the hinge region between alpha-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodies. J Biol Chem 2000; 275:6375-6380.
32. Verhamme I, Kvassman JO, Day D, Debrock S, Vleugels N, Declerck PJ, Shore JD. Accelerated conversion of human plasminogen activator inhibitor-1 to its latent form by antibody binding. J Biol Chem 1999;274:17511-17517.
33. Ehrlich HJ, Gebbink RK, Keijer J, Linders M, Preissner KT, Pannekoek H. Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties. J Biol Chem 1990;265:13029-13035.
34. James K, Taylor FB Jr, Fudenberg HH. The effect of alpha-2-macroglobulin in human serum on trypsin, plasmin, and thrombin activities. Biochim Biophys Acta 1967;133:374-376.
35. Florova G, Karandashova S, Declerck PJ, Idell S, Komissarov AA. Remarkable stabilization of plasminogen activator inhibitor 1 in a "molecular sandwich" complex. Biochemistry 2013;52: 4697-4709.